SCHEMBL462001

SCHEMBL462001

CCOCCOC(=O)C=CC#N

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.48
ALDH1A1 P00352 5/20 0.48
THRB P10828 2/20 0.43
ATM Q13315 1/20 0.42
HCAR2 Q8TDS4 5/20 0.40
TP53 P04637 2/20 0.39
HIF1A Q16665 2/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 2/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HPGD P15428 1/20 0.32
ZDHHC20 Q5W0Z9 1/20 0.32
ZDHHC2 Q9UIJ5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889687 0.98 TSHR (0.47) TSHRALDH1A1THRBATMHCAR2
SCHEMBL4888147 0.89 ATM (0.48) TSHRALDH1A1THRBATMHCAR2
SCHEMBL6466648 0.89 HCAR2 (0.54) TSHRALDH1A1ATMHCAR2MAPT
SCHEMBL3791086 0.88 TSHR (0.50) TSHRALDH1A1THRBATMHCAR2
SCHEMBL3786038 0.88 TSHR (0.50) TSHRALDH1A1THRBATMHCAR2
SCHEMBL4888226 0.87 HCAR2 (0.47) TSHRALDH1A1THRBATMHCAR2
SCHEMBL4888287 0.87 HCAR2 (0.47) TSHRALDH1A1THRBATMHCAR2
SCHEMBL35576 0.84 ATM (0.56) TSHRALDH1A1THRBATMHCAR2
SCHEMBL4889702 0.84 ATM (0.56) TSHRALDH1A1THRBATMHCAR2
SCHEMBL2897724 0.84 ALDH1A1 (0.60) TSHRALDH1A1THRBATMHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 526 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717744-A1 USE OF A COMPOSITION BASED ON CYANOACRYLATE AND (METH)ACRYLATE Bostik SA (FR) 2026-04-01 EP claimed
US-20260041183-A1 ADHESIVE FOR COSMETIC ARTICLE AND METHOD OF FORMING FULLER H B CO (US) 2026-02-12 US claimed
US-20250215132-A1 TWO-PART CURABLE COMPOSITION BOSTIK SA (FR) 2025-07-03 US claimed
WO-2025119862-A1 COMPOSITION COMPRISING N-HEPTYLCYANOACRYLATE BOSTIK SA (FR) 2025-06-12 WO claimed
EP-4567084-A1 COMPOSITION COMPRISING N-HEPTYLCYANOACRYLATE Bostik SA (FR) 2025-06-11 EP claimed
CN-116209729-B Thickener for cyanoacrylate-based adhesives 旭化成株式会社 2025-04-08 CN claimed
EP-4504844-A1 TWO-PART CURABLE COMPOSITION Bostik SA (FR) 2025-02-12 EP claimed
US-12157784-B2 Two-part curable composition BOSTIK SA (FR) 2024-12-03 US claimed
CN-114621398-B Stretchable cyanoacrylate tissue adhesives and uses thereof 香港科技大学 2024-04-30 CN claimed
CN-111615666-B Method for producing planar polymer stacks 阿科玛法国公司 2024-02-06 CN claimed
WO-2007026196-A2 QUALITY CONTROLLED ARTIFICIAL EYELASHES EXTENSION SYSTEM NOVALASH INC. (US) 2007-03-08 WO claimed
US-20070050207-A1 QUALITY CONTROLLED ARTIFICIAL EYELASHES EXTENSION SYSTEM NOVALASH INC. 2007-03-01 US claimed
US-6605667-B1 1,1-disubstituted ethylene monomers such as alpha-cyano-acrylates; storage stability CLOSURE MEDICAL CORPORATION 2003-08-12 US claimed
US-20030149128-A1 Stabilized monomer adhesive compositions CLOSURE MEDICAL CORPORATION 2003-08-07 US claimed
EP-0965623-B1 Stabilized monomer adhesive compositions CLOSURE MEDICAL CORP (US) 2003-05-02 EP claimed
US-20030082116-A1 Adhesive compositions containing dual function stabilizers and active agents CLOSURE MEDICAL CORPORATION (US) 2003-05-01 US claimed
US-6512023-B1 An adhesive composition includes a polymerizable adhesive monomer, at least one vapor phase stabilizer, and at least one liquid phase stabilizer. The combination of at least one vapor phase stabilizer and at least one liquid phase CLOSURE MEDICAL CORPORATION 2003-01-28 US claimed
US-20020055573-A1 Stabilized monomer adhesive compositions CLOSURE MEDICAL CORPORATION (US) 2002-05-09 US claimed
WO-2002020069-A2 ANTIOXIDANT ENRICHED ADHESIVE COMPOSITIONS AND STORAGE CONTAINERS THEREFOR CLOSURE MEDICAL CORPORATION (US) 2002-03-14 WO claimed
EP-0965623-A1 Stabilized monomer adhesive compositions Closure Medical Corporation (US) 1999-12-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041183-A1 ADHESIVE FOR COSMETIC ARTICLE AND METHOD OF FORMING KRT18, CDH1, CFL1 TSHR 3226/4885ALDH1A1 556/4885THRB 1859/4885
US-20030082116-A1 Adhesive compositions containing dual function stabilizers and active agents TLN1, PTK2, ILK TSHR 4697/4885ALDH1A1 812/4885THRB 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.